Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Square Pharmaceuticals's Days Inventory or its related term are showing as below:
DHA:SQURPHARMA'
s Days Inventory Range Over the Past 10 Years
Min: 74.16 Med: 95.17 Max: 122.25
Current: 114.17
During the past 13 years, Square Pharmaceuticals's highest Days Inventory was 122.25. The lowest was 74.16. And the median was 95.17.
DHA:SQURPHARMA's Days Inventory is ranked better than 73.26% of 920
companies
in the Drug Manufacturers industry
Industry Median: 164.815
vs DHA:SQURPHARMA: 114.17
Square Pharmaceuticals's Days Inventory
declined
from Mar. 2025 (124.17) to Mar. 2026 (105.53).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Square Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.86.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Square Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.60.
Square Pharmaceuticals (DHA:SQURPHARMA) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Square Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Square Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Square Pharmaceuticals Days Inventory Related Terms
Square Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Square Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:SQURPHARMA vs ZTS, UTHR: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Square Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Square Pharmaceuticals Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Square Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Square Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Square Pharmaceuticals (DHA:SQURPHARMA) has a Days Inventory of 105.53 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Square Pharmaceuticals and its competitors. This is 11% above median its historical median of 95.17. Over the past decade, Square Pharmaceuticals' Days Inventory has ranged from 74.16 to 122.25. According to the industry distribution chart, Square Pharmaceuticals ranks #246 out of 920 companies in the Drug Manufacturers industry, placing it in the top 26.7%.
Is Square Pharmaceuticals' Days Inventory too high?
Square Pharmaceuticals' current Days Inventory of 105.53 is 11% above median its 10-year median of 95.17. Over the past 10 years, this metric has ranged from a low of 74.16 to a high of 122.25. The Drug Manufacturers industry median Days Inventory is 164.82. Square Pharmaceuticals' value of 105.53 is 36% below this industry median. Based on the distribution chart, Square Pharmaceuticals ranks #246 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Square Pharmaceuticals has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Square Pharmaceuticals' Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Square Pharmaceuticals ranks #246 out of 920 companies for Days Inventory. This puts Square Pharmaceuticals in the upper half of its industry. The industry median Days Inventory is 164.82. Square Pharmaceuticals' value of 105.53 is 36% below this benchmark. Historically, Square Pharmaceuticals' own Days Inventory has ranged from 74.16 to 122.25 over the past decade. While the company's 10-year median is 95.17 vs. the industry median of 164.82, Square Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.82, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Square Pharmaceuticals's current Days Inventory of 105.53 is 36% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Square Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Square Pharmaceuticals's current Days Inventory is 105.53, which is 11% above median its own 10-year median of 95.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Square Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Square Pharmaceuticals (DHA:SQURPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is BDT219.96, compared to a current price of BDT214.70 — trading 2.4% below its estimated fair value. The current Days Inventory is 105.53, which is 11% above median its 10-year median of 95.17 and 36% below the Drug Manufacturers industry median of 164.82. Square Pharmaceuticals' overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Square Pharmaceuticals (DHA:SQURPHARMA), the current Days Inventory is 105.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Square Pharmaceuticals (DHA:SQURPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Square Pharmaceuticals stock appears to be undervalued.
The current stock price of BDT214.70 is trading 2.4% below its estimated GF Value™ of BDT219.96.
GuruFocus considers Square Pharmaceuticals to be Fairly Valued.
Key valuation signals for DHA:SQURPHARMA:
Days Inventory: 105.53 (11% above median its 10-year median of 95.17)
GF Value™: BDT219.96 vs. price of BDT214.70 (2.4% below fair value)
Industry Position: 36% below the Drug Manufacturers median (#246 of 920)
No single metric tells the full story. See the DHA:SQURPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceutical products, basic chemical products, animal health products, and crop care products, along with the manufacturing, marketing, and distribution of pharmaceutical products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs such as paracetamol, clotrimazole, antiallergic, nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs, and also provides devices such as AnsuPen and AnsuPen Twist.
94GF Score
Get the complete analysis for DHA:SQURPHARMA
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:SQURPHARMA has been successfully added to your 
